
|Videos|August 1, 2022
Dr. Stover discusses research on UGN-102 in non–muscle-invasive bladder cancer
Author(s)Urology Times staff
“UGN-102 may offer a patient-centered therapeutic approach, more patient centered than standard treatments like surgery,” says Angela M. Stover, PhD.
Advertisement
In this video, Angela M. Stover, PhD, shares the take-home message from the Journal of Urology study, “Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer,” for which she served as a study author. Stover is an assistant professor of health policy and management at the University of North Carolina, Chapel Hill.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
AI-generated profiles impersonate female urologists to market ED products online
2
Alternative BCG strains may help address ongoing supply challenges in NMIBC
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA
5






